Buehler Kevin 4

What Happened

• Kevin Buehler, a director of Precision BioSciences, had 21,000 restricted stock units (RSUs) vest on May 20, 2026. The RSUs converted into 21,000 shares of the company's common stock (recorded as a derivative conversion/exercise with a $0.00 price), i.e., no cash was paid or received in the transaction.
• This action reflects the scheduled vesting of an award rather than an open‑market buy or sale; it increases Buehler’s shareholding but does not represent an outlay or proceeds.

Key Details

• Transaction date: May 20, 2026; Form 4 filed May 22, 2026 (timely filing).
• Reported transactions: conversion/exercise of derivative (M) — 21,000 shares acquired via RSU vesting; corresponding entry shows 21,000 shares disposed at $0.00 to reflect conversion from RSUs to common stock.
• Shares owned after transaction: not provided in the excerpt supplied.
• Footnotes: F1 confirms the RSUs vested on May 20, 2026; F2 states each RSU equals one share; F3 notes the RSUs were granted on June 3, 2025 and vested on the earlier of June 3, 2026 or the day before the next annual meeting, subject to continued service.
• No 10b5-1 plan, tax withholding, or sale reported in this filing.

Context

• RSU vesting converts a contingent award into actual shares — this is generally neutral from a trading-sentiment perspective (not a purchase nor a cash sale).
• The Form shows a $0.00 price because the transaction reflects conversion/vesting rather than a funded purchase; any market value would equal the share price on the vesting date (not stated here).
• Retail investors should note this increases insider ownership but is routine compensation-based vesting rather than an indicator of active buying or selling.